Objectives: Characterization of the conditions favouring HIV-1 low-level viraemia (LLV) during treatment is required to guide strategies for prevention and cure.
Introduction
The quantification of HIV-1 RNA in plasma has been the mainstay of assessments of HIV replication and efficacy of ART for almost 20 years. The first assays had a limit of quantification (LOQ) of 400 copies/mL, but new technologies with an LOQ of 40 or 20 copies/mL have greatly improved the sensitivity. 1, 2 The clinical significance of this low-level viraemia (LLV) is a matter of debate. 3, 4 Most guidelines indicate that treatment should aim to achieve a viral load (VL) ,50 copies/mL, but treatment failure is still defined as a confirmed value above 200 or even 400 copies/ mL. 5 -8 The range of 50 -200 copies/mL is thus a 'grey zone' in that there is no consensus regarding patient management. Doubts about the origin of LLV partly account for this situation. An artefactual HIV-DNA quantification in improperly processed samples has been reported. 9 -11 The activation of latently infected cells and/or the continuous expression of an HIV proviral reservoir, as well as ongoing viral replication in sanctuaries, may be potential sources, although these hypotheses have been mainly proposed for viraemia ,50 copies/mL. 3, 12, 13 The consequences of LLV are also widely debated. Some authors have suggested that viraemia below 200 or even 50 copies/mL may be predictive of subsequent treatment failure or associated with the development of drug resistance, 14 -19 whereas others refer to a large retrospective analysis reporting no difference between virological failure thresholds of 200 and 50 copies/mL. 20, 21 Regardless of the causes and consequences of LLV, no study has yet shown how to restore these cases of LLV to levels , 50 copies/mL. The principal approach is therefore the avoidance of conditions favouring LLV. We aimed to identify the characteristics and treatments of patients with confirmed LLV (PLLVs) through comparisons with patients with persistent controlled viraemia below the LOQ (PPCVs). We also identified factors affecting replication levels and the presence of resistance-associated mutations (RAMs). Finally, we compared the outcome for PLLVs with no evidence of HIV resistance as a function of the presence or absence of treatment modification.
Patients and methods

Study population and control group
We searched the laboratory database for HIV-1-infected patients receiving treatment who had LLV (a range of 50 -1000 copies/mL) in two consecutive tests performed from 2008 to 2011. LLV1 and LLV2 were defined as the two first LLVs found consecutively for a particular individual in that period. Patients were selected consecutively and once only. In terms of the duration and composition of treatment, the conditions commonly accepted as achieving or maintaining HIV-1 viraemia at levels ,50 copies/mL were required. Patients were therefore included in line with the following criteria: (i) patients were receiving HAART including at least three antiretroviral drugs from at least two different classes; (ii) patients were either in rebound, i.e. had achieved virological success (two consecutive VLs ,50 copies/mL) just before LLV1 on the same HAART (PLLVAs), or had already persistent LLV for at least 1 year before LLV1 despite continuous HAART (that had been stable for at least 6 months; PLLVBs). We excluded patients being treated for hepatitis and those with incomplete viro-immunological follow-up since the time of HIV diagnosis. We selected 171 PLLVs (107 PLLVAs and 64 PLLVBs) in total. The 107 PLLVAs had achieved virological success for a median of 14 months (IQR 8 -23 months) before LLV1. The control group of PPCVs had to have had viraemia consistently below the LOQ for more than 24 months, i.e. beyond the last quartile observed for the PLLVAs (23 months). This period could include VL measurements after the time of selection, and patients had to be maintained on the same HAART, with at least three VL determinations per year. Period bias was avoided by selecting PPCVs retrospectively and only once from among the subjects undergoing viraemia determinations in the same week as the PLLVs with whom they were matched.
HAART groups
HAART was classified into four groups according to its composition. Patients receiving therapies based on three drugs, including two NRTIs plus one NNRTI, a PI or raltegravir (an integrase inhibitor), were defined as the tNNRTI, tPI and tRAL groups, respectively. All other alternative regimens including more than three drugs and/or maraviroc and/or enfuvirtide were assigned to the 'AltTrt' group.
HIV-1 VL and genotypic resistance testing (GRT)
Only historical measurements of viraemia performed after November 2006 were considered, when the first and second versions of Roche Cobas CA/CTM assays (Roche, Meylan, France) were available for quantifying viraemia down to 50 copies/mL, with LOQs of 40 and 20 copies/mL, respectively. The pre-analytical steps were optimal to prevent any artefactual HIV-DNA quantification. Whole blood had been collected in EDTA tubes, shipped to the laboratory and centrifuged within 12 h. Plasma was tested rapidly or transferred into a secondary tube before freezing.
GRT was performed on LLV2 plasma samples. The list of mutations from the International AIDS Society was used to establish the presence of RAMs. For PIs, we considered only primary mutations. A RAM was considered to be 'new' if it had not previously been reported in the patient's history or if no previous GRT data were available, because it was considered as new information provided by the GRT for treatment management. We defined three groups, as follows: failure of GRT (NoGRT), any RAM detected (ResGRT) and no RAM detected (WtGRT). The genotypic susceptibility score (GSS) for a HAART was calculated by adding the susceptibility scores of the component drugs as follows: susceptible¼ 1, intermediate resistance ¼ 0.5 and resistance ¼ 0, in accordance with the 2013 ANRS HIV-1 algorithm (www.hivfrenchresistance.org).
Statistical analysis
The parameters investigated in a logistic regression model were age, sex, the nadir CD4 count (the lowest value since diagnosis), the zenith VL (the highest value since diagnosis), the number of years since diagnosis, the number of years on continuous HAART treatment, the number of lines of treatment before inclusion and the presence of any RAM in the patient's history. Variables yielding a P value ,0.20 in univariate analysis were selected for a stepwise inclusion procedure in the multivariate model. Depending on the number of groups and the expected values, categorical variables were compared using the x 2 or Fisher's exact tests, with Wilcoxon or Kruskal -Wallis tests used to compare continuous variables. Values of P, 0.05 were considered statistically significant.
Results
Risk factors for PLLVs
The characteristics and treatments of the 171 PLLVs and 146 PPCVs are compared in Tables 1 and 2 . Three factors were identified as independent predictors of PLLVs: a higher zenith VL (5.27 versus 4.91 log 10 copies/mL; OR 2.23; P ¼0.0003), a shorter time on continuous HAART (4.3 versus 6.8 years; OR 0.88; P ¼ 0.0003) and the presence of any RAM in the patient's history (43% versus 23%; OR 2.42; P ¼ 0.0033). The number of lines of treatment before inclusion was also significant in univariate analysis, but excluded in the multivariate model because of collinearity with the presence of any RAM in the patient's history. In terms of treatment (Table 2) , PLLVs received the same proportion of tPI regimens as PPCVs, but fewer tNNRTI regimens (12.4% versus 32.2%; P, 0.0001) and more AltTrt regimens (18.2% versus 3.4%; P, 0.0001). Both efavirenz and nevirapine were less frequently used in PLLVs than in PPCVs, whereas the use of etravirine, darunavir and maraviroc was more frequent in PLLVs. However, associations were found between patients' characteristics and their treatments ( Table 3 ). The patients in the tRAL and AltTrt groups had received almost three times as many lines of treatment as those in the other groups and also had the highest frequency of previous resistance. In a subanalysis, the patients taking etravirine or darunavir also had a higher frequency of previously reported RAMs than those receiving another drug from the same class (87% versus 9%, and 64% versus 29%, respectively; P, 0.0001 in both cases). Thus, the most recent drugs and AltTrt regimens were used in patients with the heaviest treatment histories and resistance backgrounds. Conversely, the tNNRTI group had several points in common with the PLLV group: the lowest rate of previous RAMs and the longest period Wirden et al.
of continuous HAART (P ¼ 0.0055; Table 3 ), particularly in comparison with the tPI group (8.5 versus 4.8 years, respectively). Interestingly, analyses of the PPCV control group only showed that the period of the unchanged continuous regimen was still longer for patients in the tNNRTI group than for those in the tPI group (4.3 versus 3.3 years; P ¼ 0.003). This suggests that NNRTI-based regimens may be more stable than PI regimens, regardless of the LLV context.
Level of LLV and resistance mutations in PLLVs
The 75th and 90th percentiles for viraemia in PLLVs were 180 and 422 copies/mL for LLV1, respectively, and 196 and 463 copies/mL for LLV2, respectively. Thus, despite the use of criteria allowing the inclusion of patients with viraemia of up to 1000 copies/mL, at least 75% and 90% of LLV values were below 200 and 500 copies/mL, respectively. LLV1 and LLV2 were not statistically different, with median values of 101 and 108 copies/mL, respectively. The median difference (LLV2 minus LLV1) was +10 copies/mL with an interval of 2.5 months between the two measurements. These results did not differ between treatment groups, but they did differ between GRT groups (Figure 1 ). The ResGRT group (n¼61, 36%) had significantly higher levels of viraemia than the NoGRT (n¼68, 40%) and WtGRT (n¼42, 24%) groups and was the only group to display a significant, albeit very small, difference between LLV1 and LLV2 (+0.11 log copies/mL; P ¼ 0.024). Above the threshold of 200 copies/mL (with the NoGRT group excluded), there tended to be more patients in the ResGRT group (72% versus 53%; P ¼ 0.07), and there were about twice as many new RAMs than were seen with a VL ,200 copies/mL (53% versus 25%; P¼ 0.006; Figure 2 ).
The multivariate analysis identified two factors as independent predictors of resistance mutations at the time of LLV2: a lower Table 4 ). The proportion of patients from the ResGRT group was similar for the PLLVAs (35%) and PLLVBs (37%) and 83% of these individuals received a treatment with a GSS score ,3. RAMs tended to be more frequent with tRAL treatment, but they were already present in most patients' histories and were new information for only 43% of them ( Figure 3 ). New RAMs were observed in 20% of the 171 PLLVs, 34% of the LLV2 GRT group and 57% of the ResGRT group. They tended to be more frequent in patients receiving tNNRTIs than in patients on other regimens (53% versus 30%; P ¼0.09).
Treatment interventions and outcomes for PLLVs receiving effective HAART
We assessed the best way to manage PLLVs receiving a treatment presumed to be fully effective by retrospectively observing, when possible, the outcomes for 111 patients from the NoGRT (n¼ 65) and WtGRT (n ¼38) groups and for patients in the ResGRT group who were receiving HAART with a GSS that remained ≥3 (n¼ 8). Wirden et al.
The treatment was modified after LLV2 (in terms of the choice of drugs or their dosage) for 60 patients (the Change group) and remained unchanged in the other 51 patients (the NoChange group). The frequency of patients for whom virological success was re-established (two consecutive VLs ,50 copies/mL) did not differ significantly between the Change and NoChange groups (58% versus 53%; P ¼ 0.7) during a median follow-up of 13 and 16 months (P¼0.62), respectively. Similarly, the median change in CD4 cell count was comparable: +73 versus +54 CD4 cells/mm 3 (P ¼ 0.92). The treatment changes were too diverse for a more detailed analysis. However, the success rates were highest (6/6) for changes involving an increase in the dose of a PI (atazanavir or darunavir). In four cases, PI concentrations were suboptimal before the dose increase. Among the 53 patients in the ResGRT group with a GSS ,3, 83% (n ¼ 44) had their treatment modified, with a virological success of 70% (31/44) versus 33% for the patients with no change in their treatments.
Discussion
In this study, we aimed to determine the conditions associated with LLV through comparisons with individuals in whom viraemia Risk factors for HIV low-level viraemia was persistently maintained below the LOQ. We studied several aspects of this issue, which may involve many factors. This, together with the precise selection criteria and confirmed LLV with consensual and stable treatments, is a particular strength of this study. The first analysis showed that PLLVs had a higher zenith VL and had been on continual HAART for shorter periods. These findings are consistent with those of a previous study reporting a higher zenith VL and higher viraemia before the initiation of therapy for patients with a persistent LLV of 20 -250 copies/mL. 22 They are also consistent with the reactivation of latently infected cells being one of the sources of LLV. Indeed, higher zenith VL values generate a larger reservoir and thus a greater capacity to release detectable numbers of HIV. 12 A longer duration of continuous HAART may therefore be required to decrease the size of this reservoir and to minimize the risk of repeated LLV. As observed in PPCVs, a median duration of 7 years of continuous treatment may be required to prevent LLV. This implies the use of a stable, sustainable antiretroviral regimen for several years to keep the viraemia below the LOQ.
In this study, the frequency of tNNRTI use in PLLVs was only one-third that in PPCVs. This may be due to the low barrier to genetic resistance and the high-level cross-class resistance observed for first-generation NNRTIs. These problems prevent the use of these drugs in patients with a history of NNRTI resistance or a risk of poor adherence to treatment. However, previous studies have also reported links between NNRTI regimens and an absence of LLV or a higher frequency of PI-based regimens in PLLVs. 14, 22, 23 Moreover, we found that the patients treated with tNNRTI regimens had the longest durations of continuous HAART and the smallest number of lines of treatment (Table 3 ). Limiting our analysis to PPCVs to eliminate the context of LLV and suspected poor adherence, we again observed that tNNRTI was associated with longer periods on the same continuous HAART regimen than were seen for patients receiving tPI. Thus, in addition to the better penetration of NNRTIs into 'sanctuaries' that has been described by other authors, 14, 24 these observations suggest that NNRTI-based treatments may form the basis of more stable regimens that can be administered without interruption over several years, such conditions being associated with a lower risk of LLV over time, as shown above. Better long-term tolerability, longer half-lives and fewer pharmacological interactions with other drugs may account for the sustainability of such treatments. 25, 26 However, further studies focusing specifically on this issue are required to confirm this hypothesis.
In contrast to the observations for efavirenz and nevirapine, the most recent compounds (etravirine, darunavir, raltegravir and maraviroc) were more frequently used in PLLVs than in PPCVs (Table 2) . Indeed, during the study period, these new drugs and new classes of drugs were initially used in the patients with the heaviest treatment histories, particularly those displaying resistance to the oldest drugs (Table 3 and Figure 3 ). The use of these drugs is therefore more likely to reflect a history of heavy treatment rather than being the cause of LLV. After 2011, the wider use of these compounds at earlier stages of treatment may have generated different results. The potential role of drug resistance in the ongoing replication of HIV led us to our second hypothesis concerning the origin of LLV. Indeed, the presence of any RAM in a patient's history was also identified as a risk factor for belonging to the PLLV group, independently of the zenith VL and the duration of HAART (Table 1) . Moreover, RAMs were also found to be associated with a higher level of viraemia and a significant increase between LLV1 and LLV2, as well as with a lower zenith VL. All these findings confirm that resistance mutations, whether already recorded in the patient's history or discovered during LLV, constitute a second factor associated with LLV, independently of a high zenith VL inducing large viral reservoirs.
Overall, these data are consistent with the two hypotheses on the biological origin of LLV, both of which may apply within a single patient. The first hypothesis involves a higher zenith VL and a larger HIV reservoir, leading to the release of HIV and requiring several years of stable, continual treatment to reduce it. The second hypothesis involves ongoing replication, with RAMs either already present or emerging. Tobin et al. 13 put forward the same conclusion following a sequencing analysis of LLV.
Another interesting result of this study is the level of LLV reported. In the present study, 90% and 75% of values for viraemia were below 500 and 200 copies/mL, respectively. Thus, confirmed or persistent LLV in the range of 500-1000 copies/mL appears to be uncommon. Laprise et al. 18 recently reported a much higher risk of experiencing viraemia of more than 1000 copies/mL for patients with LLV in this range (almost five times higher versus twice as high). Thus, the virological outcome is clearly different above 500 copies/mL and, contrary to what is observed in many studies, 15, 16, 18, 19, 27 such viraemia should be considered purely as treatment failure rather than LLV. Moreover, the use of an upper cut-off point of LLV closer to the thresholds defining virological failure-500 or 200 copies/mLwould clarify debates on this issue.
The final aim of this work was to describe the management of patients experiencing LLV with no evidence of drug resistance. Our findings indicate that treatment modification is no more effective than the status quo for achieving virological success in the following months. Previous studies have also shown that changes to the treatment regimen had no impact on residual viraemia. 28, 29 These observations provide support for the hypothesis that, in the absence of RAMs, the origin of LLV is likely to be release from a reservoir, which can be resolved by treatment for longer periods, as demonstrated in the first analysis in this study. However, improvements in treatment adherence, as probably claimed by physicians, may contribute to these results. Increasing the dose of darunavir or boosting atazanavir also appeared to be an effective intervention. One of the limitations of this study is the absence of more extensive pharmacological data that could provide useful information about suboptimal drug concentrations.
In conclusion, the present study provided objective data to define LLV as viraemia below 500 copies/mL or even 200 copies/mL. LLV is associated with a high zenith VL, a shorter duration of HAART and the presence of previously detected or new RAMs. Our findings confirm that HAART during the earliest stages of HIV infection, particularly during primary infection, must be useful for minimizing the zenith VL. Otherwise, patients may require several years of uninterrupted HAART to prevent LLV originating from the viral reservoir. To this end, the advantage of NNRTI-based regimen requires confirmation in other studies. As LLV can also originate from ongoing replication, genotyping may be useful for assessing the presence of resistance and adapting the antiretroviral regimen, even for viraemia below 200 copies/mL. In the absence of RAMs, virological success is achieved in similar proportions of patients with or without changes to their treatment. However, more comprehensive prospective studies are required to determine what specific intervention, such as an increase in PI dose, is an effective way of increasing the rate of virological success in such a context of LLV.
